Jefferies Assumes TherapeuticsMD (TXMD) at Buy

November 22, 2016 6:40 AM EST
Get Alerts TXMD Hot Sheet
Price: $5.46 -2.85%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade TXMD Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies assumes coverage on TherapeuticsMD (NYSE: TXMD) with a Buy rating and a price target of $18.00.

Analyst Matthew Andrews commented, "Assuming with Buy and $18 PT. TXMD is focused on women's health and we believe its bioidentical hormone replacement therapies (TX-001HR and Yuvvexy) for moderate/severe menopausal symptoms due to VMS and VVA offer innovation and clinical differentiation from existing HRTs and have blockbuster sales potential with combined peak sales of $4.5B."

For an analyst ratings summary and ratings history on TherapeuticsMD click here. For more ratings news on TherapeuticsMD click here.

Shares of TherapeuticsMD closed at $6.96 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Jefferies & Co

Add Your Comment